Bio-Rad Laboratories
Supplies droplet digital PCR, clinical-laboratory systems, reagents, controls, and recurring consumables.
Something off on this page? Send us feedback.
Profile
Sells instruments, systems, reagents, assays, controls, and consumables through Life Science and Clinical Diagnostics. Revenue leans toward clinical diagnostics, while recurring products connect many instruments to laboratory workflows and Droplet Digital PCR anchors the clearest current platform expansion.
Operates through Life Science and Clinical Diagnostics. Life Science spans molecular biology, PCR and Droplet Digital PCR, protein analysis, chromatography, cell biology, and single-cell workflows; Clinical Diagnostics covers quality controls, blood typing, diabetes and hemoglobin testing, autoimmune and infectious-disease testing, and multiplex immunoassays.
Pairs installed instruments and systems with assays, reagents, media, controls, and other consumables across laboratory workflows. A global research, manufacturing, and sales network serves universities, research institutions, hospitals, biopharmaceutical companies, and clinical laboratories.
Depends on research funding and biopharma demand in Life Science, and on regulatory clearance, quality systems, laboratory adoption, and reimbursement in Clinical Diagnostics. Repeated acquisitions underpin the Droplet Digital PCR platform, while founder-family voting control shapes governance. Fair-value changes in the external Sartorius stake flow through reported earnings without making Sartorius an operating segment.
Company facts
Key statistics
Year to date +27.0% · Average volume (30d) 293.6K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Reiterate | Outperform | $370 | $390 | |
| Aug 5, 2026 | RBC Capital | Reiterate | Outperform | $320 | $370 | |
| May 25, 2026 | Wells Fargo | Target | $290 | $310 | ||
| May 14, 2026 | RBC Capital | Target | $565 | $320 | ||
| May 1, 2026 | Wells Fargo | Reiterate | Equal Weight | $320 | $290 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | $1.75 | $2.62 | +49.7% | $624.0M | $651.0M | +4.3% | +4.50% |
| Apr 30, 2026Q1 FY26 | $1.99 | $1.89 | −5.0% | $589.9M | $592.1M | +0.4% | −8.41% |
| Feb 12, 2026Q4 FY25 | $2.57 | $2.51 | −2.3% | $688.8M | $693.2M | +0.6% | −12.26% |
| Oct 29, 2025Q3 FY25 | $2.30 | $2.26 | −1.7% | $694.6M | $653.0M | −6.0% | −4.65% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $585.4M | $651.6M | $653.0M | $693.2M | $592.1M | $651.0M | |
| Gross profit | $306.0M | $345.3M | $343.4M | $345.2M | $309.4M | $345.8M | |
| Operating income | $23.7M | $77.1M | $66.4M | $61.9M | $34.1M | $72.6M | |
| Net income | $64.0M | $317.8M | −$341.9M | $720.0M | −$527.1M | $371.4M | |
| Diluted EPS | $2.29 | $11.67 | −$12.70 | $26.65 | −$19.55 | $13.85 | |
| Gross margin | 52.3% | 53.0% | 52.6% | 49.8% | 52.3% | 53.1% | |
| Operating margin | 4.0% | 11.8% | 10.2% | 8.9% | 5.8% | 11.2% |
Fiscal years (4-quarter sums)FY21 $2.92B · FY22 $2.80B · FY23 $2.67B · FY24 $2.57B · FY25 $2.58B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $1.62B · Total debt $1.20B · Total assets $10.25B · Shareholders' equity $7.17B
Dividends
No dividends on record.
Ownership
Shares outstanding 26.92M · Float 17.88M · 66.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Norman D. Schwartz | 3.23M | 14.60% | 13D | Oct 30, 2025 |
| Alice N. Schwartz | 2.73M | 12.30% | 13D | Jul 18, 2025 |
| First Eagle Investment Management, LLC | 2.61M | 9.68% | 13F | Aug 24, 2026 |
| BlackRock, Inc. | 1.70M | 6.31% | 13F | Aug 7, 2026 |
| The Bank of Nova Scotia | 1.60M | 6.50% | 13D/G | Oct 10, 2024 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 11, 2026 | Eva Anette Engelhardt | officer: EVP, President, CDG | −550 | $246.54 |
| Nov 6, 2025 | James Barry | officer: EVP, President, LSG | −700 | $306.18 |
Peers
- Danaher
Broad overlap across bioprocessing, life-science tools, and diagnostics
- Thermo Fisher Scientific
Extensive overlap in PCR, protein analysis, cell biology, and bioprocessing
- Waters
Overlaps in flow cytometry, molecular diagnostics, and clinical workflows
- Abbott
Competes in core-lab, molecular, and cardiometabolic diagnostics
- QIAGEN
Closest specialist overlap in digital PCR and molecular workflows
- QuidelOrtho
Focused overlap in clinical immunoassay, blood typing, and infectious testing
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Bio-Rad Laboratories | $387.70 | +0.02% | $10.44B | 47.0 | 37.6 | 4.0 | −0.1% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Waters | $414.33 | −0.03% | $31.02B | 103.4 | 26.5 | 6.7 | +113.3% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| QIAGEN | $43.00 | −0.28% | $8.89B | 22.1 | 17.3 | 4.2 | +0.3% |
| QuidelOrtho | $14.70 | −0.27% | $1.01B | — | 17.5 | 0.4 | +2.6% |
| Median | 36.2 | 21.5 | 4.6 | +8.0% |